Minimally Invasive Sx Use Up for Paraesophageal Hernia Repair

Share this content:
Minimally Invasive Sx Use Up for Paraesophageal Hernia Repair
Minimally Invasive Sx Use Up for Paraesophageal Hernia Repair

FRIDAY, Aug. 25, 2017 (HealthDay News) -- A minimally invasive surgery (MIS) approach is increasingly being used for paraesophageal hernia (PEH) repair, accounting for almost 80 percent of PEH repairs in 2012, according to a research letter published online Aug. 23 in JAMA Surgery.

Patrick J. McLaren, M.D., from the Oregon Health and Science University in Portland, and colleagues conducted a retrospective review of inpatient admissions for PEH repair extracted from the Nationwide Inpatient Sample. Data relating to 97,393 PEH repairs were extracted from the database. The authors examined the proportion of PEH repairs performed via the MIS approach over time.

The researchers found that the proportion of MIS repairs increased from 9.8 percent in 2002 to 79.6 percent in 2012 (odds ratio, 1.66). This increase correlated with a reduction in in-hospital mortality (from 3.5 to 1.2 percent; odds ratio, 0.90) and decreased rates of any complication (from 29.8 to 20.6 percent; odds ratio, 0.95) over the study period. MIS was associated with significantly reduced rates of intraoperative injury and in-hospital mortality compared with open procedures (0.6 versus 3.0 percent), and with reduced wound, bleeding, urinary, septic, respiratory, and cardiac complications. Compared with an open approach, MIS lead to significantly shorter mean length of stay (4.2 versus 8.5 days). No significant difference was seen in thromboembolic complications between MIS and open approaches.

"Our findings are consistent with prior reports of improved outcomes with MIS, and the data demonstrate widespread adoption of MIS for PEH repair on a national level," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »